Search results
Results from the WOW.Com Content Network
CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development. Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the ...
For premium support please call: 800-290-4726 more ways to reach us
Alexandria Real Estate Equities, Inc. is a real estate investment trust based in Pasadena, California that invests in office buildings and laboratories leased to tenants in the life science and technology industries. [1] The company also has a venture capital arm, Alexandria Venture Investments, which invests in life sciences firms. [2]
For premium support please call: 800-290-4726 more ways to reach us
Moderna (MRNA) stock is up 2.7% in Thursday's pre-market trading after the company inked a deal with Vertex Pharmaceuticals for the treatment of cystic fibrosis (CF) using gene editing.Moderna and ...